Oct 4, 2004|
Pharma R&D: A new paradigm
Recently, Glenmark Pharma, a mid-cap Indian pharma company, out-licensed one of its molecules to the US based Forest Laboratories for further clinical trials and marketing rights for the US markets. This was the biggest deal of its kind by any Indian pharma company. Also, this is for the first time that a small Indian company has come up with a breakthrough product. While this has been made possible by the R&D activity that Glenmark has been pursuing, for the Indian pharma sector as a whole, there is still a long way to go.
R&D is increasingly becoming an area of focus for Indian pharma companies and most of the big companies are spending about 6%-7% of their revenues on R&D activity. While this is much lower when compared to the amount spent by global pharma majors towards R&D activity (around 12%-15% of revenues), it must be noted that since Indian companies are operating at the lower end of the value chain, they cannot afford higher R&D expenses.
Going back to the early 1990's, Indian companies started their drug discovery programs with Dr. Reddy's and Ranbaxy leading the front. While in early days, Indian companies were involved in recognizing lead molecules and out-licensing several of them at pre-clinical stages, now the scene is changing and Indian companies are conducting clinical trials of drugs on their own. For instance, Ranbaxy is conducting clinical trial phase II of its asthma compound (Rbx 7796) in Europe while Dr. Reddy's is conducting clinical trail phase I of its anti-diabetes compound (DRF 10945) in Canada.
While bigger companies like Dr. Reddy's and Ranbaxy are much ahead in terms of R&D activity and their new drug pipeline, smaller companies are catching up fast with companies as small as Dabur Pharma having 2 molecules in pipeline.
Indian Pharma companies New drug Pipeline
* One of Ranbaxy's Drug Delivery product ("Cipro OD) is in market
While there are stories of success for Indian companies on the R&D front, there are failures too. For instance, trials on two of Dr. Reddy's out-licensed molecules have been stopped/suspended. On the other hand, some major successes on this front include Ranbaxy's drug delivery product Cipro OD, which was out-licensed to Bayer AG and is already in the market. Ranbaxy has received almost US$10 m in royalty payment. Apart from that, another molecule of Ranbaxy, which was licensed to Schwarz Pharma, is doing well and Ranbaxy is receiving milestone payments for that.
Apart from this, Indian companies are also entering into R&D alliances with international pharma majors. Ranbaxy is again leading with an alliance with Glaxo SmithKline Pharma through a drug discovery and clinical trial deal. This deal provides Ranbaxy access to large database of drugs of Glaxo as well as critical technologies for drug discovery, while Glaxo benefits from Ranbaxy's drug discovery and early product development strength.
R&D is a high risk - high return business and it is too early for Indian companies to deliver start-to-finish NCE (new chemical entities) products. However, the licensing deals, which have come up in the past few years show the ability of Indian pharma companies towards innovation. While generics, in the near to medium term, will continue to be the growth driver, companies that will keep investing their earnings into R&D activity will move up the value chain and transcend into new growth trajectory in the long run. We firmly believe that Indian companies have the ability for this paradigm shift over the next few years. And when that happens, we shall see a Indian powerhouse of innovation in drug discovery.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407